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1. Introduction
People with chronic kidney disease (CKD) develop changes in circulating blood levels of
calcium and phosphorus. The kidney gradually loses the ability to remove phosphorus from
the blood and cannot produce adequate amounts of active vitamin D to maintain normal
levels of calcium. This occurs mainly because of decreased renal excretion of phosphate and
diminished renal hydroxylation of 25-hydroxyvitamin D to calcitriol due to low expression
of alpha-1-hydroxylase in the failed kidneys [1]. Further compensation to maintain normal
serum calcium and phosphorus homeostasis includes increased production and release of
parathyroid hormone (PTH) and potentially other phosphaturic factors, such as fibroblast
growth factor-23 (FGF23) [2].
Two main complications follow to the above mentioned molecular responses namely secon‐
dary hyperparathyroidism (sHPT) and vascular calcification (VC), which occur in a high
percentage of CKD patients [1]. These molecular disorders alter bone metabolism which
leads to bone abnormalities including altered bone production and resorption. In turn, bony
changes may result in bone deformation, bone pain, and more risks of fracture [3]. All of the
above biochemical abnormalities (calcium, phosphorus, vitamin D and PTH disturbances)
and vascular calcification as well as changes in bone metabolism such as variation in turn‐
over and bone mineralization can be included under the descriptions for CKD-associated
mineral and bone disorders (CKD-MBD) [4].
This review explains the main pathological causes and mechanisms of CKD-MBD and the
possible animal models for basic research on this disease. It also describes some clinically
applicable diagnosis techniques and treatment methods with their advantages and side ef‐
fects for CKD-MBD.
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2. Potential pathological mechanisms
2.1. sHPT-related bone disorders
The first changes that usually occur with the decline of renal function involve the deficiency
of active vitamin D and decrease in phosphorus excretion by the remaining functional neph‐
rons [5]. In CKD, the failed kidney is inefficient in alpha-1-hydroxylase expression resulting
in low synthesis of calcitriol. Simultaneously the kidney with lower function has reduced
ability to reabsorb calcium from urine [6]. Therefore, low serum calcium level, high serum
phosphorus level and impaired renal 1, 25-dihydroxyvitamin D synthesis with attendant re‐
duction in serum calcitriol concentration and decrease in vitamin D receptor expression in
the parathyroid glands contribute to excess PTH secretion in patients with CKD [7].
PTH strongly influences the exchange of calcium to and from bone through its involvement
in bone cell apoptosis mechanisms and effects on the receptor activator of NF-kappa B
(RANK)/receptor activator of NF-kappa B ligand (RANKL)/osteoprotegerin (OPG) axis.
Continuously elevated PTH could upregulate RANKL expression, leading to an increase in
the formation rate and survival time of bone-resorbing osteoclasts and net bone loss [8, 9].
Excess PTH also leads to high bone turnover, a condition characterized by accelerated rates
of bone formation and bone resorption [1]. The high bone turnover due to sHPT is accompa‐
nied by about 5% (up to 10%) lower bone mass, which is partly reversible (low mineral
bone, increased remodeling space) and partly irreversible (cortical thinning) [10]. The new
formed bone in the course of sHPT is structurally inferior and fragile, and carries an in‐
creased risk of fractures.
Another main molecular mechanism underlying sHPT is attributed to Klotho-fibroblast
growth factor-23 (FGF-23) system. Humans with CKD experience decreased Klotho expres‐
sion as early as stage 1 CKD. Klotho continues to decline as CKD progresses, causing
FGF-23 resistance and provoking large FGF-23 and parathyroid hormone increases [11].
FGF-23 is a novel bone-derived hormone, in conjunction with its co-receptor, Klotho, acti‐
vates FGF receptor 1 (FGFR1) and acts on the kidney to induce renal phosphate wasting and
to suppress 1,25-dihydroxyvitamin D synthesis [12]. In patients with CKD, circulating
FGF23 levels are progressively increased to compensate for persistent phosphate retention,
but this result in reduced renal production of 1, 25-dihydroxyvitamin D through suppress‐
ing 1α-hydroxylase activity, which leads to sHPT [13].
2.2. VC-related bone disorders
Vascular calcification is very common in patients with CKD, appearing in 30-65% of patients
with stage 3-5 CKD, 50-80% of patients with stage 5 CKD [14]. Calcium, a divalent cation,
and phosphate, a trivalent anion, have a high binding affinity for one another and as the
concentration of one or both ions increases in serum, there is an increased risk for an ionic
bond to form, creating an insoluble complex which leads to vascular calcification [5]. Clini‐
cally, when the serum calcium-phosphate product exceeds 60 mg2/dl2, widespread tissue
deposition of amorphous calcium phosphate occurs [15].
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There are a large number of promoters and inhibitors involved in vascular calcification and
there are more vascular calcification inhibitors circulating in the blood under normal condi‐
tions [1]. Phosphorus is the most significant studied vascular calcification promoter which is
available at higher level in patients with low renal function. Hyperphosphatemia reverses
the normal process in which calcification inhibitors are down-regulated, while promoters
are up-regulated [1].
On the other hand, many bone-associated proteins including osteocalcin, osteopontin and
osteoprotegerin,  and many bone morphogenetic  proteins  are  involved in  the  process  of
VC [16].  Previous studies have proven that active mineralization mechanisms clearly re‐
sembling those of skeletal endochondral and membranous ossification participate in vas‐
cular  calcium accumulation [17].  The findings  of  bone-related factors  in  the  vasculature
and  the  vascular  calcification  observed  in  several  gene-knockout  mouse  models  imply
that  CKD-MBD  is  an  actively  regulated  process  that  may  be  preventable  or  even  re‐
versed [18]. The most striking among these mouse models is the matrix gamma-carboxy‐
glutamic acid (Gla)  protein (MGP) knockout mouse,  which exhibits  extensive and lethal
calcification and cartilaginous metaplasia of the media of all elastic arteries as early as 2
weeks after  birth [19,  20],  indicating that  this  protein may be of  primary importance in
human vascular calcification [18].
3. Clinical diagnosis
3.1. Biomarkers
According to the standardized diagnostic criteria for CKD-MBD developed and published
by the international expert consensus group, kidney disease improving global outcomes
(KDIGO), monitoring serum levels of calcium, phosphorus, PTH, and alkaline phosphatase
is strongly recommended, and the frequency of monitoring is based on the occurrence and
extent of abnormalities as well as the rate of CKD progression [21]. Phosphorus level equal
to the upper phosphorus level of 5.5 mg/dL and calcium level more than 9.5 mg/dL have
been suggested to be associated with increased mortality in CKD patients [22]. The com‐
bined use of second- and third-generation PTH assays allows to measure PTH (1–84) and
PTH (7–84) as PTH (7-84) interacts with distinct receptors and thereby may have important
roles in the regulation of bone resorption and serum calcium concentration [23]. The fre‐
quency of measurement on alkaline phosphatases is very similar to that of PTH and can pro‐
vide additional information on bone turnover. The recent more KDIGO guidelines
recommend that the measurement on alkaline phosphatase levels should commence in stage
3 of CKD, and that in patients with stage 4-5 of CKD, alkaline phosphatase should be meas‐
ured at least every 12 months [24].
The first measurable biomarker in urine is the decline of secreted Klotho expression (as de‐
tected by western blotting of concentrated urine samples, normalized to the same creatinine
content) occurs as early as stage 1 of CKD [25], therefore, Kuro-O contends that decreased
Klotho expression is the initiator of CKD-MBD pathophysiology and is potentially an early
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clinical marker of CKD [11]. The study, performed on sixty pre-dialysis patients with CKD
1-5, showed that the changing of serum OPG level happened at the earliest time (CKD 3)
and its correlation coefficient with estimated glomerular filtration rate (eGFR) and BMD of
Ward's triangle was statistically high, suggesting serum OPG may be a useful biomarker for
early diagnosis of CKD-MBD [26], additionally, the multivariate analysis demonstrated that
OPG was associated with aortic stiffness in patients with CKD stages 3-4, indicating OPG is
also a marker to evaluate the cardiomyocyte dysfunction of CKD-MBD [27].
3.2. Imaging
Histomorphometry remains the gold standard to evaluate bone, but it is rarely performed in
clinical practice. Areal measurement of bone mineral density by dual-energy x-ray absorpti‐
ometry (DEXA) is routinely performed to evaluate bone mass. However, this technique
presents some limitations. In 2000, the United States National Institutes of Health defined
new "quality" criteria for the diagnosis of osteoporosis in addition to decreased bone mass.
Bone strength actually integrates two concepts: bone quantity and bone quality (i.e., micro‐
architectural organization, bone turnover, bone material properties such as mineralization,
collagen traits, and micro-damage) that cannot be evaluated by DEXA. New three-dimen‐
sional, noninvasive bone-imaging techniques have thus been developed, e.g., high-resolu‐
tion peripheral quantitative computed tomography (HR-pQCT). HR-pQCT allows
evaluation of both volumetric density and microarchitecture in different compartments of
bone [28]. Bacchetta reported for the first time an early impairment of trabecular microarchi‐
tecture in stage 2-4 CKD patients using a noninvasive bone-imaging device, HR-pQCT [29].
Physicians usually use a variety of noninvasive imaging tools to identify VC, some with
merely qualitative and others with both qualitative and quantitative capabilities. Plain x-
rays and ultra-sonography can be used to identify macroscopic calcification of aorta and pe‐
ripheral arteries, and computed tomography technologies constitute the gold standard for
quantification of cardiovascular calcification [30].
4. Clinical treatment strategy
The clinical treatment for CKD-MBD targets the possible pathological mechanisms of main‐
ly sHPT and VC in patients with kidney failure as treating these abnormalities will have a
direct positive impact on preventing the metabolic bone disease. However, the heterogenei‐
ty of CKD-MBD makes strict protocol-driven therapeutic approaches difficult. Accordingly,
considerable individualized therapy is required [31]. The followings are currently the most
common and effective intervening methods.
4.1. Phosphate binders
In patients at stage 3-5 of CKD, multiple studies from different parts of the world have
shown that higher levels of serum phosphorus have been associated with an increased rela‐
tive risk of mortality [24]. Many clinical trials show that phosphate binders are effective in
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reducing serum phosphorus and PTH levels [32]. Therefore, the use of phosphate binders
might be a promising and most practical strategy for the prevention of VC and sHPT which
are the main pathological manifestations of the metabolic bone disease in CKD patients. The
following categories of phosphate binders are being applied clinically so far:
1. Aluminum-based phosphate binders are the first type of phosphate binders to be used.
They are very effective at controlling phosphorus. The most common binder of this type
is aluminum hydroxide. However, aluminum has toxic effects on bone and nervous
system. For this reason, aluminum-based phosphate binders are not often used much
anymore [33].
2. Calcium-based phosphate binders are effective in binding phosphates and can be
source of calcium. Common types of calcium-based binders include calcium acetate and
calcium carbonate, both of which could cause the elevation of free calcium cation level
in the gastrointestinal tract and the subsequent increase of intestinal calcium absorption
[34]. The Japanese Society of Dialysis Therapy (JSDT) clinical practice guideline has rec‐
ommended a higher level of these oral phosphate binders as the upper limit for clinical
use [35]. These binders can also serve as calcium supplements if the calcium is low.
However, if the patient is taking vitamin D supplements, he/she may already have high
calcium levels, and these types of phosphate binders may provide more calcium than
the normal level (i.e., excess calcium load). Therefore using calcium based phosphate
binders should be accompanied with monitoring calcium levels and it should be pre‐
scribed while limiting total calcium intake.
3. Aluminum-free, calcium-free phosphate binders are newer binders that are effective at
controlling phosphorus. Because they do not contain aluminum or calcium, they do not
cause problems with excess aluminum or calcium load. Lanthanum carbonate is a novel
non-calcium, non-aluminum phosphate-binding agent, and has been approved for clini‐
cal use in patients on hemodialysis in Japan on March in 2009 [33]. Sevelamer is a poly‐
meric amine, which is the only non-absorbed, non-calcium-based phosphate binder
currently indicated for phosphate control. The first formulation of sevelamer to be ap‐
proved was sevelamer hydrochloride, while a newer formulation, sevelamer carbonate,
has more recently become available [36]. Sevelamer carbonate was developed to offer
phosphorus lowering while eliminating the risk of worsening metabolic acidosis associ‐
ated with sevelamer hydrochloride and the consequent need to monitor for changes in
serum chloride or bicarbonate levels [37].
4.2. Vitamin D compounds
Vitamin D analogues suppress PTH synthesis and secretion in patients with sHPT. Reple‐
tion with native vitamin D may lead to improved control of secondary hyperparathyroidism
in patients with CKD which reduces the risk of bone mineral disease. It has been demon‐
strated that treatment with vitamin D analogues can decrease mortality in dialysis patients
[38]. There might be some differences in clinical outcomes among vitamin D compounds
with fewer calcemic and phosphatemic effects [39], such as paricalcitol, doxercalciferol, and
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maxacalcitol. Therefore, it is important for desirable active vitamin D compounds to achieve
optimal vitamin D receptor (VDR) activation without inducing hypercalcemia. It is likely
that the elevated calcium levels caused by calcitriol may be directly and/or indirectly re‐
sponsible for the relative risk of the cardiovascular diseases that are aggravated by hypercal‐
cemia in patient populations.
4.3. Calcimimetics
Calcimimetics bind to the calcium sensing receptor (CaSR) in parathyroid gland and mimic
the effect of an elevated extracellular ionized calcium concentration. These molecules reduce
serum levels of PTH and calcium, with a leftward shift in the set-point for calcium-regulated
PTH secretion [40]. Cinacalcet is the only clinically available calcimimetic and has been
shown to be a very effective therapeutic compound in the metabolic bone disease associated
with CKD. Many clinical trials with cinacalcet in hemodialysis patients have shown a reduc‐
tion in parathyroid hormone, calcium, phosphate and calcium × phosphate product levels,
allowing far greater success in reaching therapeutic goals as recommended by international
guidelines [41]. In addition to effective control of secondary hyperparathyroidism, treatment
with cinacalcet may improve the mineral balance in patients with dialysis who have serum
phosphate/calcium disequilibrium, and furthermore helps treating the vascular calcification
as well. While, calcimimetics are not approved for use in paediatric patients with CKD and
long-term data on their effects on bone, growth and biochemical parameters in children are
lacking. Thus, further studies are warranted to determine the optimal strategy for control‐
ling secondary hyperparathyroidism in the paediatric CKD population [42].
4.4. Administering BMP-7
One of the bone morphogenetic proteins,  BMP-7, also known as osteogenic protein 1,  is
highly expressed in the adult kidney, and circulates in the bloodstream [43]. Therefore, it
is apparent that the decrease of renal mass results in the decreased production of BMP-7,
causing mineral bone disease in CKD patients [44].  One may expect an accumulation of
osteoblast precursors as stimulated by PTH in CKD. While, these progenitors may be un‐
able to differentiate mature osteoblasts because of BMP-7 deficiency considering it is im‐
portant  in  osteoblast  development  and  function.  In  this  situation,  the  subsequent
accumulation of fibrous cells could then offer an explanation for the marrow fibrosis ob‐
served in secondary hyperparathyroidism in the setting of CKD and applying BMP-7 ex‐
ternally  can  heal  the  disorder.  There  are  an  increasing  number  of  recent  clinical  trials
that provide supportive evidence for the use of BMP-7 in the treatment of fractures and
bone  nonunions  [45].  It  is  not  yet  started  to  use  BMP-7  as  a  routine  clinical  treatment
tool except for trials in patients even though many of the studies have shown the bone
healing efficacy of this molecule.
4.5. Surgery on thyroid gland
A surgical  correction in the parathyroid gland is  the final,  symptomatic  therapy for the
most severe forms of sHPT which cannot be controlled by the above medical treatments.
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The  2009  KDIGO  guideline  suggested  parathyroidectomy  to  patients  who  are  at  CKD
stages 3-5 with severe hyperparathyroidism and fail to respond to medical/pharmacologi‐
cal  therapy  [46].  There  are  two  main  surgical  procedures  which  are  generally  used,
namely  subtotal  parathyroidectomy  and  total  parathyroidectomy  with  immediate  auto‐
transplantation. The number and size of affected parathyroid glands are the most impor‐
tant  factors  for  selecting  the  treatment  procedure  [47,  48].  Clinical  studies  proved  that
parathyroidectomy with autotransplantation from forearm was significantly effective and
safe in patients in whom medical  treatment had failed,  particularly in terms of improv‐
ing calcium and phosphate control [49, 50]. The procedure need to be performed as early
as  possible  to  avoid  the  adverse,  irreversible  effects  of  prolonged hyperparathyroidism,
and to improve osteoarticular symptoms. Future strategies may focus on the stimulation
of apoptotic activity of hyperplastic parathyroid cells [51].
5. Animal models
5.1. 5/6 nephrectomy model
Experimental model of 5/6 nephrectomy or the remnant kidney model represents one of
the most used animal models of progressive renal failure by reducing nephron number,
best-characterized in rats  [52].  The reduction of  renal  mass is  achieved by either  infarc‐
tion or surgical excision of both poles, with removal of the contra-lateral kidney. The 5/6
nephroctomy model has been found to produce serum creatinine level which is on aver‐
age 2.2-fold higher than control animals, and thereafter, if without the concurrent use of
vitamin  D,  the  phosphorus  level  after  8  weeks  of  surgery  would  range  up  to  2.6-fold
higher than control animals [53].  Increased fibrosis,  increased number of osteoblasts and
osteoclasts as well as a mineralization defect (increased osteoid volumes and osteoid sur‐
face),  those  of  which  are  typical  bone  changes  upon  sHPT,  have  been  observed  in  5/6
nephrectomy animal models [14].
The operation of 5/6 nephrectomy, combining with a diet containing 1.2% P plus 0.6% Ca,
could effectively induce sHPT in rats [54]. Additionally, the progressive partial nephrecto‐
my with thyroparathyroidectomy (TPTx-Nx) reduced the storage modulus, which is a me‐
chanical factor, in CKD model rats as compared with controls that underwent
thyroparathyroidectomy alone (TPTx). Moreover, the TPTx-Nx rats exerted different cortical
bone chemical composition and increased enzymatic crosslinks ratio and pentosidine to ma‐
trix ratio [55].
As concerned as VC associated with CKD-MBD, it can be induced in 5/6 nephrectomy rat
model by feeding a high-phosphorus, high-lactose diet (1.2% P, 1% Ca, and 20% lactose) af‐
ter 10 weeks follow up for the reason that lactose increases calcium and phosphorus absorp‐
tion in intestine [56].
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5.2. Electrocautery models
In the mouse electrocautery model, CKD is induced by surgical ablation of the kidneys. This
is a two-step procedure. Initially the cortex of one kidney is electrocauterized paying careful
attention to avoid destroying the adrenals and the hilum of kidney. One week later, once the
animals have recovered, the second kidney is nephrectomized [44]. This procedure appears
to produce variable severity of CKD with blood urea levels ranging from 1.5- to 4.8-fold
higher than normal animals [53]. This murine model displayed an increase in osteoblast sur‐
face and osteoid accumulation as well as increased activation frequency and increased os‐
teoclast surface consistent with high turnover renal osteodystrophy [44]. Lund developed a
standard CKD rat models by involving electrocauthery of the right kidney followed by
nephroctomy of the left kidney, and found that there was a significant hyperosteoidosis pro‐
duced in this model as a result of the secondary hyperparathyroidism [57].
5.3. Adenine-contained diet
Normally, adenine is efficiently salvaged by adenine phosphoribosyltransferase (APRT) and is
present at very low level in blood and urine. APRT is involved in the conversion of adenine to
adenosine monophosphate. When adenine is administered in high level, APRT activity is satu‐
rated and adenine is oxidized to 2,8-dihydroxyadenine. Adenine and 2,8-dihydroxyadenine
are excreted in the urine. However, the very low solubility of 2,8-dihydroxyadenine results in
its precipitation in the kidney. The accumulation of insoluble 2,8-dihydroxyadenine results in
nephrolithiasis and renal failure with permanent kidney damage. Induction of chronic renal
failure (CRF) in mice by dietary administration of 0.75% adenine for 4 weeks results in irrever‐
sible renal dysfunction and then CKD [53]. High-adenine feeding in rats results in the forma‐
tion  of  crystals  in  the  renal  tubules,  with  subsequent  tubular  injury  and  inflammation,
obstruction, and marked fibrosis [56]. Future investigations of the biochemical basis for the link
between vascular calcification and bone resorption will be facilitated by the present discovery
that a synthetic, 2.5% protein diet containing 0.75% adenine produces consistent and dramatic
medial calcification in adult rats within just 4 weeks [58].
5.4. Gene knockout mice
JCK mouse is a genetic model of polycystic kidney disease. At 6 weeks of age, the mice
have  normal  renal  function  and  no  evidence  of  bone  disease  but  exhibit  continual  de‐
cline in renal  function and death by 20 weeks of  age,  when approximately 40% to 60%
of them have vascular calcification. Temporal changes in serum parameters of JCK mice
relative to wild-type mice from 6 through 18 weeks of age were shown to largely mirror
serum  changes  commonly  associated  with  clinical  CKD-MBD.  Bone  histomorphometry
revealed  progressive  changes  associated  with  increased  osteoclast  activity  and  elevated
bone formation [59].
Klotho null mice display premature aging and CKD-MBD-like phenotypes mediated by hyper‐
phosphatemia and remediated by phosphate-lowering interventions (diets low in phosphate or
vitamin D; knockouts of 1α-hydroxylase, vitamin D receptor, or NaPi cotransporter) [11].
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5.5. Obstructive nephropathy
The mouse with unilateral ureteral obstruction (UUO) is a well-established model of tubuloin‐
terstitial fibrosis of the kidney as the interstitial fibrosis is a hallmark of chronic renal failure
[60]. We previously reported the vitamin D signaling attenuates renal fibrosis in obstructive
nephropathy by suppressing the renin-angiotensin system (RAS) [61], furthermore, we found
the mice developed hypocalcaemia and hyperparathyroidism after 7 days of ureteric obstruc‐
tion [62], and the down-regulation of Cbfa1 and Col mRNA expression (Fig. 1) and the up-regu‐
lation of Tgf-β, CtsK, CaII, Opg and Rankl mRNA expression (Fig. 2) in tibia of UUO mice as well
as the microarchitectural changes in the proximal tibia, likely to be precursors of the early stage
during CKD-MBD [62]. The pathological alterations of proximal tibia in UUO group were char‐
acterized by a marked expansion of hypertrophic zone of chondrocytes and a dramatic de‐
crease  in  osteoid  content  of  the  primary  spongiosa  zone,  where  the  immature,  poorly
mineralized woven bones were present,  indicating impaired mineralization of the newly
formed bones (Fig. 3B). Above all, in addition to established genetic pathways, we suggest that
the local skeletal renin-angiotensin system may be involved in the bone deteriorations associat‐
ed with CKD as demonstrated by the marked up-regulation of protein expression of angioten‐
sin II and its type 2 receptor in tibia of UUO mice (Fig. 4) [62].
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Figure 1 mRNA expression of osteoblast-specific 
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Figure 1. mRNA expression of osteoblast-specific genes in tibia of sham-operated and UUO mice
 
 
β
    
   
 
    
    
 
 
   
   
   
Figure 2 mRNA expression of osteoclast-specific 
β
β  
Sham UUO 
CtsK 
CaII 
β2m 
Figure 2. mRNA expression of osteoclast-specific genes in tibia of sham-operated and UUO mice
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Figure 3 Hematoxylin and Eosin staining of the proximal tibia. The chondrocyte zone at growth plate 
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Figure 3. Hematoxylin and Eosin staining of the proximal tibia. The chondrocyte zone at growth plate was shown in A
(Sham) and B (UUO) and it was visually separated into two areas, proliferative zone (PZ) and hypertrophic zone (HZ).
Calcified cartilage with overlying newly bone underneath growth plate is known as the primary spongiosa (PS). Mag‐
nification, ×100.
 
 
  
 
 
  
   
  
  
 
Figure 4 Protein expression of RAS components in mice tibia 
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Figure 4. Protein expression of RAS components in mice tibia
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6. Conclusion
In summary, the present review demonstrates that the main pathological mechanisms in‐
volved in CKD-MBD are secondary hyperparathyroidism and vascular calcification. There‐
fore the main focus of the therapeutic research and the further molecular investigations
should be on these main abnormalities associated with CKD. This can be achieved by em‐
ploying the proper animal models for each of these complications including genetically
modified mouse models. The animal models can play a great role in understanding the un‐
derlying mechanisms for CKD-MBD. The clinical treatment approaches should depend on
the specific levels of the biomarkers of CKD patients. Further studies are needed to discover
other pathological mechanisms for CKD-MBD other than those explained here. More ad‐
vanced basic medical sciences should also be performed on the research and development of
novel drugs with less adverse effects.
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